AIM Vaccine (HKG:6660) submitted the application for clinical trial of the iterative-process of its human diploid serum-containing rabies vaccine to the Center for Drug Evaluation of the National Medical Products Administration of China, a Thursday Hong Kong bourse filing said.
The company has already developed an iterative-process high-efficiency human diploid rabies vaccine workshop, up to the international standards, which is capable of large-scale production of the drug. The company has also produced commercial-scale phase 3 clinical trial samples of the drug.
Compared to other rabies vaccines in the market, the company's vaccine has overcome the blockages of low virus titer and low yield in the traditional process.
The vaccine has been optimized and innovated along with optimizing its safety and quality and its vaccination process is more flexible than the traditional drugs in the market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。